How a Global Privacy Standard Can Boost Patient Trust
Regulations that apply across geographic borders can provide researchers and patients a firmer foundation on data protection.
Simultaneous New Drug Submissions: Is it Possible?
A roadmap to avoiding the common pitfalls of concurrent FDA-EMA filings.
Key Guidance Updates in 2022
Summarizing important FDA and EMA revisions issued this year.
Tips and Tools to Overcome DE&I Challenges in Clinical Trials
Navigating FDA’s draft guidance and heightened diversity recommendations.
First-hand Perspectives on Achieving True Digital Health Engagement
Final presentation at DIA reminds: "we are all patients."
Identifying Important Risk Indicators in Clinical Development
Study indentifies trends in most commonly used KRIs.
Using Solid Endpoint Strategies for Successful Cancer Trials
Nabil Chehab, medical affairs head of lung cancer franchise at AstraZeneca, discuss strategies used in the Phase III AEGEAN trial for treating non-small lung cancer (NSCLC).
Europe’s Debate on AMR Becomes Another Proxy War Over Money
Debates caught between focusing on existing antibiotics and developing new agents.
Pandemic Spurred New R&D Approaches from Pharma, FDA in 2022
Looking back on major FDA moves in 2022.
From Present to ‘Post’: Holdover Trends to Watch
Industry straddling two worlds as new year approaches.
Applied Clinical Trials December 2022 Issue (PDF)
Click the title above for a link to open the Applied Clinical Trials December 2022 issue in an interactive PDF format.
Understanding Project Optimus
Why oncology needs dosing redesign.
